Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies in East Asia and many other parts of the world ^[@R1]^. Genetic factors play an important role in the etiology of both sporadic and familial CRC ^[@R2]^. However, less than 6% of CRC cases can be explained by rare, high-penetrance variants in the CRC susceptibility genes identified to date, such as the *APC*, *SMAD4*, *AXIN2*, *BMPR1A*, *POLD1*, *STK11*, *MUTYH*, and DNA mismatch repair genes ^[@R2]^. Over the past two decades, many candidate gene studies have evaluated common genetic risk factors for CRC; only a few of them have been replicated in subsequent studies ^[@R3]^. Recent genome-wide association studies (GWAS) have identified approximately 15 common genetic susceptibility loci for CRC ^[@R4]--[@R12]^. However, these newly identified genetic factors, along with known high-penetrance CRC susceptibility genes, explain less than 15% of the heritability for this common malignancy ^[@R10],\ [@R11]^. Furthermore, with the exception of a small study conducted in Japan ^[@R12]^, all other GWAS were conducted among European-ancestry populations which differ from other ethnic groups in certain genetic architecture. Many of the variants discovered in European-ancestry populations show only a weak or no association with CRC in other ethnic groups ^[@R13]^. Therefore, additional GWAS are needed, particularly in non-European-ancestry populations, to fully uncover the genetic basis for CRC susceptibility.

In 2009, we initiated the Asia Colorectal Cancer Consortium (ACCC), a GWAS in East Asians, to search for novel genetic risk factors for CRC. The discovery stage (Stage 1) consisted of five GWAS conducted in China, Korea, and Japan, including 2,293 CRC patients and 5,780 controls ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Cases and controls were genotyped using several SNP arrays, including Affymetrix Genome-Wide Human SNP Array 6.0 (906,602 SNPs), Affymetrix Genome-Wide Human SNP Array 5.0 (443,104 SNPs), Illumina Infinium HumanHap610 BeadChip (592,044 SNPs), Illumina Human610-Quad BeadChip (620,901 SNPs), and Illumina HumanOmniExpress BeadChip (729,462 SNPs) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). After quality control (QC) exclusions as described previously ^[@R14]--[@R17]^, 2,098 cases and 5,749 controls remained for this study ([Supplementary Tables 1 and 2](#SD1){ref-type="supplementary-material"}). Also excluded from the analyses were SNPs with a call rate \< 95%, genotype concordance rate \< 95% among positive QC samples, minor allele frequency (MAF) \< 5%, or *P*-value for Hardy-Weinberg equilibrium \< 1.0 × 10^−5^ in controls for each study. Imputation was conducted for each study following the MACH algorithm ^[@R18]^ using phased HapMap 2 CHB and JPT samples as the reference. No apparent genetic admixture was identified except for one sample from KCPS-II ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Associations between CRC risk and each of the genotyped and imputed SNPs were evaluated using logistic regression within each study after adjusting for age, sex, and the first ten principal components using mach2dat ^[@R18]^. Meta-analyses were conducted under a fixed-effects model using the METAL program ^[@R19]^. There was little evidence for inflation in the association test statistics for any of the five studies (genomic inflation factor (λ) range: 1.02 to 1.04) or for all studies combined (λ= 1.01) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"} and [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). The observed number of SNPs with a small *P*-value was slightly larger than that expected by chance ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}).

Multiple genomic locations were revealed as potentially related to CRC risk ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Nine SNPs identified from published GWAS conducted in European-ancestry populations showed an association with CRC risk at *P*\< 0.05 in Stage 1 (data not shown). To improve the statistical power for evaluating these SNPs, we genotyped 6,476 additional samples to bring the total sample size to 5,252 cases and 9,071 controls. Except for the two SNPs (rs6691170 and rs16892766) that are monomorphic in East Asians, all 16 of the other SNPs identified from published GWAS conducted in European-ancestry populations showed an association with CRC risk in the same direction as reported previously ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). A significant association with CRC risk at *P* \< 0.05 was found for 13 SNPs, including rs6687758, rs10936599, rs10505477, rs6983267, rs7014346, rs10795668, rs3802842, rs4444235, rs4779584, rs9929218, rs4939827, rs10411210, and rs961523. Except for two SNPs (rs6983267 and rs4779584), no statistically significant heterogeneity at *P*\< 0.05 was observed between East-Asian- and European-ancestry populations ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

To identify novel genetic factors for CRC, we selected 64 SNPs for replication in an independent set of 5,358 cases and 5,922 controls recruited in five studies conducted in China, Korea, and Japan ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). SNPs were selected from among those with 1) MAF \> 5%; 2) no heterogeneity across studies (*P*~heterogeneity~\> 0.05 and *I*^2^ \< 25%); 3) not in linkage disequilibrium (LD) (*r*^2^\< 0.2) with any known CRC risk variants reported from previous GWAS; 4) high imputation quality in each of the five studies (RSQ \> 0.5); 5) *P*\< 0.01 in the combined analysis of all five studies included in Stage 1. These criteria were used to prioritize SNPs for replication for this study.

Of the 64 SNPs evaluated in Stage 2, seven SNPs showed an association with CRC risk at *P*\< 0.05 with a direction of association consistent with that observed in Stage 1 ([Table 1](#T1){ref-type="table"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). In the combined analysis of data from both Stages 1 and 2, *P*-values for the association with two SNPs (rs647161 at 5q31.1, OR=1.17, *P* = 3.77 × 10^−10^ and rs10774214 at 12p13.32, OR=1.17, *P* = 5.48 × 10^−10^) were lower than the conventional genome-wide significance level of 5.0 × 10^−8^, providing convincing evidence for an association of these SNPs with CRC risk ([Table 1](#T1){ref-type="table"}). An additional SNP, rs2423279, showed a significant association in Stage 2 after Bonferroni correction (corrected *P*\< 7.8 × 10^−4^), but did not reach the conventional GWAS significance level for association with CRC risk in the combined analysis of all samples (OR=1.14, *P* = 2.29× 10^−7^). The association between CRC risk and each of these three SNPs was consistent across most studies ([Fig. 1](#F1){ref-type="fig"}). Results for the other four SNPs (rs1665650, rs2850966, rs1580743, and rs4503064) replicated in Stage 2 at *P*\< 0.05 are also presented in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}, including one SNP (rs1665650) with a *P*-value of 8.58 × 10^−7^ in the combined analysis of all data from both stages ([Table 1](#T1){ref-type="table"}).

We next evaluated these top four SNPs shown in [Table 1](#T1){ref-type="table"} using data from GWAS in the Genetics and Epidemiology of Colorectal Cancer Consortium and the Colon Cancer Family Registry (GECCO and CCFR), which include 11,870 cases and 14,190 controls of European ancestry ^[@R4],\ [@R20],\ [@R21]^. Three of the four SNPs were replicated in the GECCO and CCFR, although the strength of the association was weaker than that found in East Asians ([Table 2](#T2){ref-type="table"}). These results provide independent support of our findings in the East Asian population. Meta-analyses of data from both East Asian and European populations provided strong evidence for associations of CRC risk with three SNPs with *P*-values all exceeding the genome-wide significant threshold of 5 × 10^−8^ ([Table 2](#T2){ref-type="table"}). The weaker associations observed in European-ancestry populations could be explained in part by differences in LD patterns for these loci for East Asians and Europeans ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). It is possible that causal variants in these regions are tagged by different SNPs in these two populations or there is allelic heterogeneity, in which different underlying causal variants exist in Asian- and European-ancestry populations. The difference in LD structure between Asian and European descendants and possible allelic heterogeneity in these two populations may explain, in part, why these loci were not discovered in previous studies conducted in European descendants. The fourth SNP, rs1665650 evaluated in in the GECCO and CCFR, however, was not replicated in European-ancestry populations (OR = 0.96, *P* = 0.05).

Stratification analyses showed that the associations of CRC risk with each of these three replicated SNPs were generally consistent in Chinese, Korean, and Japanese (*P*~heterogeneity~ \> 0.05), although the association with rs2423279 was not statistically significant in the Japanese, perhaps due to a small sample size ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Associations of these three SNPs with CRC risk were similar for men and women (*P*~heterogeneity~ \> 0.05) ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}).

SNP rs10774214 is located just 15 kb upstream of *CCND2*, the gene encoding cyclin D2 ([Figure 2](#F2){ref-type="fig"}), a member of the D-type cyclin family, which also includes cyclins D1 and D3. These cyclins play a critical role in cell cycle control (from G1 phase to S phase) through activation of cyclin-dependent kinases (CDK), primarily CDK4 and CDK6 ^[@R22]^. *CCND2* is closely related to *CCND1*, a well-established human oncogene ^[@R22],\ [@R23]^. Although *CCND2* has been less well studied than *CCND1*, several studies including The Cancer Genome Atlas (TCGA) have shown *CCND2* to be overexpressed in a substantial proportion of human colorectal tumors ^[@R22]--[@R25]^. Overexpression of this cyclin may be an independent predictor of survival in CRC patients ^[@R24]^. Several other genes, including *PARP11*, *FGF23, FGF6*, *C12orf5,* and *RAD51AP1*, are also in close proximity to the SNP identified in our study, of which both *C12orf5* (also known as *TIGAR,* TP53-induced glycolysis and apoptosis regulator) and *RAD51AP1* were found to be overexpressed in CRC tissue included in TCGA ^[@R25]^. SNP rs10774214 is in strong LD with several SNPs that are located in potential transcription sites as determined by the TRANSFAC database ^[@R26]^. Additional research may be warranted regarding possible mechanisms by which this SNP is related to CRC risk.

SNP rs647161 is located on chromosome 5q31.1, where a cluster of SNPs were associated with CRC risk ([Figure 2](#F2){ref-type="fig"}). Of the genes in this region (including *PITX1*, *CATSPER3*, *PCBD2*, *MIR4461*, and *H2AFY), PITX1* is the closest to rs647161 (approximately 129 kb upstream). The *PITX1* (*paired-like homeodomain 1*) gene has been described as a tumor suppressor gene and may be involved in the tumorigenesis of multiple human cancers ^[@R27]--[@R31]^, including CRC ^[@R27],\ [@R32]^. *PITX1* has been reported to suppress tumorigenicity by down-regulating the RAS pathway, which is frequently altered in colorectal tumors ^[@R27]^. Inhibition of *PITX1* induces the RAS pathway and tumorigenicity, and restoring *PITX1* in colon cancer cells inhibits tumorigenicity ^[@R27]^. It also has been reported that *PITX1* may activate *P53*^[@R33]^ and regulate telomerase activity ^[@R34]^. Consistent with the role of a tumor suppressor, this gene has been found to be down-regulated in human cancer tissue samples and cell lines ^[@R27]--[@R30],\ [@R32]^. CRC tissue expressing wild-type KRAS showed significantly lower expression levels of *PITX1* than tissue with mutant KRAS ^[@R32]^. Most recently, low *PITX1* expression was found to be associated with poor survival in CRC patients ^[@R35]^. In addition, rs6596201 in moderate LD with rs647161 (*r*^2^=0.25), is an eQTL (*P*=2.42×10^−28^) for the *PITX1* gene ^[@R36]^. Several other genes, including *C5orf24*, *H2AFY*, and *NEUROG1*, at this locus were also found to be highly expressed in colorectal tumors included in the TCGA (*P*\<0.001) ^[@R25]^. Additional studies are warranted to explore any possible role of these genes in the etiology of CRC.

SNP rs2423279 is located on chromosome 20p12.3, close to the *HAO1* and *PLCB1* genes ([Figure 2](#F2){ref-type="fig"}). *HAO1* encodes hydroxyacid oxidase, which has 2-hydroxyacid activity. *PLCB1* encodes phospholipase C beta 1, which plays an important role in the intracellular transduction of many extracellular signals. Overexpression of the *PLCB1* gene has been observed in CRC tissue ^[@R25]^. Possible mechanisms by which these genes are involved in CRC carcinogenesis are unknown. SNP rs2423279 is 1,408,069 bp downstream of rs961253, a SNP previously identified in a European GWAS to be associated with CRC risk ^[@R10]^. However, these two SNPs are not correlated in East Asians (*r*^2^=0) or in Europeans (*r*^2^=0). Adjustment for rs961253 did not change the results for rs2423279 (data not shown).

To our knowledge, this is the largest GWAS performed for CRC in East Asians, a population that differs from the European-ancestry population in CRC risk and certain aspects of genetic architecture. Our study, along with data from a large study conducted in a European-ancestry population, provides convincing evidence of association with CRC risk for three novel independent susceptibility loci at 5q31.1, 12p13.32, and 20p12.3. Results from this study provide new insights into the genetics and biology of CRC.

URLs {#S2}
====

CGEMS, <http://cgems.cancer.gov/>; dbGaP, <http://www.ncbi.nlm.nih.gov/gap>; EIGENSTRAT, [genepath.med.harvard.edu/\~reich/EIGENSTRAT.htm](genepath.med.harvard.edu/~reich/EIGENSTRAT.htm); [eqtl.uchicago.edu](eqtl.uchicago.edu), <http://eqtl.uchicago.edu/Home.html>; GTEx eQTL Browser, <http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi>; Haploview, <http://www.broad.mit.edu/mpg/haploview/>; HapMap project, <http://hapmap.ncbi.nlm.nih.gov/>; IntOGen, <http://www.intogen.org/home>; LocusZoom, <http://csg.sph.umich.edu/locuszoom/>; MACH 1.0, <http://www.sph.umich.edu/csg/abecasis/MACH/>; mach2dat, <http://www.sph.umich.edu/csg/abecasis/MACH/>; METAL, <http://www.sph.umich.edu/csg/abecasis/Metal/>; PLINK version 1.07, <http://pngu.mgh.harvard.edu/~purcell/plink/>; R version 2.13.0, <http://www.r-project.org/>; SAS version 9.2, <http://www.sas.com/>; SNAP, <http://www.broadinstitute.org/mpg/snap/>; TRANSFAC, <http://www.gene-regulation.com/pub/databases.html>; UCSC Genome Browser, <http://genome.ucsc.edu/>.

ONLINE METHODS {#S4}
==============

Study populations {#S5}
-----------------

After quality control (QC), 7,456 cases and 11,671 controls from ten studies were included in this consortium ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Detailed descriptions of participating studies and demographic characteristics of study participants are provided in [Supplementary Note](#SD1){ref-type="supplementary-material"}. Briefly, the consortium included 10,730 Chinese participants, 5,544 Korean participants, and 2,853 Japanese participants. Chinese participants were from five studies: Shanghai Study 1 (Shanghai-1, *n* = 3,102), Shanghai Study 2 (Shanghai-2, *n* = 485), Guangzhou Study 1 (Guangzhou-1, *n* = 1,613), Guangzhou Study 2 (Guangzhou-2, *n* = 2,892), and Guangzhou Study 3 (Guangzhou-3, *n* = 2,638). Korean participants were from three studies: the Korean Cancer Prevention Study-II (KCPS-II, *n* = 1,301), the Seoul Study (*n* = 1,522), and the Korea-National Cancer Center (Korea-NCC) Study (*n* = 2,721). Japanese participants were from two studies: Aichi Study 1 (Aichi-1, *n* = 1,346) and Aichi Study 2 (Aichi-2, *n* = 1,507). We also evaluated associations for the top four SNPs using data from 11,870 CRC cases and 14,190 controls of European ancestry included in the Genetics and Epidemiology of Colorectal Cancer Consortium and the Colon Cancer Family Registry (GECCO and CCFR), which include 14 studies from the USA, Europe, Canada and Australia ^[@R4],\ [@R20],\ [@R21]^. Approval was granted from the relevant institutional review boards at all study sites, and all included participants gave informed consent.

Genotyping and QC procedures {#S6}
----------------------------

For detailed descriptions of genotyping and QC procedures, and design for plates and QC samples, see the [Supplementary Note](#SD1){ref-type="supplementary-material"}. Briefly, in Stage 1, 481 cases and 2,632 controls from Shanghai-1 were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 as described previously ^[@R14]^. The average concordance percentage of QC samples was 99.7% with a median value of 100% in Shanghai-1 ^[@R14],\ [@R37],\ [@R38]^. Stage 1 genotyping for 296 cases and 257 controls in Shanghai-2 was performed using Illumina HumanOmniExpress BeadChips. The same method was used to genotype cases from the Guangzhou-1 (*n*= 694) and Aichi-1 (*n* = 497) studies in Stage 1. The positive QC samples in these studies had an average concordance percentage of 99.41% and a median value of 99.97%. Cases and controls in KCPS-II were genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0 ^[@R16]^. Controls for the Guangzhou-1 and Aichi-1 studies were genotyped previously using the Illumina Human610-Quad ^[@R15]^ and Illumina Infinium HumanHap610 BeadChip ^[@R17]^ platforms, respectively. Details of QC procedures for these samples have been described previously ^[@R15]--[@R17]^. Excluded from the analysis were samples that were genetically identical or duplicated, had a genotype-determined sex inconsistent with self-reported data, had unclear population structure, had close relatives with a PI-HAT estimate greater than 0.25 or had a call rate \< 95%. Within each study, SNPs were excluded if: 1) MAF \< 5%, 2) call rate \< 95%, 3) genotyping concordance percentage \< 95% in QC samples, 4) *P*-value for Hardy-Weinberg equilibrium \< 1.0 × 10^−5^ in controls, or 5) SNPs not in the 22 autosomes. The final numbers of cases, controls, and SNPs remaining for analysis in each participating study are presented in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Genotyping for Stage 2 was completed using the iPLEX Sequenom MassARRAY platform as described previously ^[@R14],\ [@R39]^. With the exception of some samples from Guangzhou study, which were genotyped at Fudan University (Shanghai, China), all other samples were genotyped at the Vanderbilt Molecular Epidemiology Laboratory. The average concordance percentage of the genotyping data for positive QC samples was \> 99% with a median value of 100% for each of the five studies. SNPs were excluded from the analysis if: 1) call rate \< 95%, 2) genotyping concordance percentage \< 95% in QC samples, 3) unclear genotyping cluster, or 4) *P*-value for Hardy-Weinberg equilibrium \< 7.8 × 10^−4^. The numbers of SNPs remaining for analysis in each participating study in Stage 2 are presented in the [Supplementary Note](#SD1){ref-type="supplementary-material"}.

Genotyping for samples included in the GECCO and CCFR GWAS was conducted using Illumina BeadChip arrays, with the exception of the Ontario Familial Colorectal Cancer Registry study, for which Affymetrix arrays were used ^[@R4],\ [@R20],\ [@R21]^. Details of the QC procedures for these samples are presented in the [Supplementary Note](#SD1){ref-type="supplementary-material"}.

SNP selection for replication {#S7}
-----------------------------

SNPs were selected for Stage 2 replication based on the following criteria: 1) data available in each of the five Stage 1 studies; 2) MAF \> 5% in each Stage 1 study; 3) no heterogeneity across the five studies included in Stage 1 (*P*~heterogeneity~\> 0.05 and *I*^2^\< 25%); 4) not in LD (*r*^2^\< 0.2) with any known risk variants reported from previous GWAS; 5) not in LD (*r*^2^\< 0.2) with each other; 6) high imputation quality in each of the five studies (RSQ \> 0.5), and 7) *P*\< 0.01 in combined analysis of all Stage 1 studies.

Evaluation of population structure {#S8}
----------------------------------

We evaluated population structure in each of the five participating studies included in Stage 1 by using principal components analysis (PCA). Genotyping data for uncorrelated, genome-wide SNPs were pooled with data from HapMap to generate the first ten principal components using EIGENSTRAT software ^[@R40]^ (see **URLs**). The first two principal components for each sample were plotted using R (see **URLs**). We identified and excluded one participant of KCPS-II who was more than 6 σ away from the means of PC1 and PC2 ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). The remaining 7,847 samples showed clear East Asian origin, and these samples were included in the final genome-wide association analysis. Cases and controls in each of the five studies were in the same cluster as HapMap Asian samples. The estimated inflation factor λ ranged from 1.02 to 1.04 in these studies after adjusting for age, sex, and the first ten principal components with a λ of 1.01 for combined Stage 1 data ([Supplementary Table 1](#SD1){ref-type="supplementary-material"} and [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}).

Imputation {#S9}
----------

We used the program MACH 1.0 ^[@R18]^(see **URLs**)to impute genotypes for autosomal SNPs which were present in HapMap Phase II release 22 separately for each of the five studies included in Stage 1. Genotype data from the 90 Asian subjects from HapMap were used as reference. For Guangzhou-1 and Aichi-1, cases and controls were genotyped using different platforms. To improve imputation quality ^[@R41]^, we identified SNPs shared between cases and controls (250,612 SNPs in Guangzhou-1 and 232,426 SNPs in Aichi-1) and used them to impute genotyping data. A total of 1,636,380 genotyped SNPs or imputed SNPs with high imputation quality (RSQ \> 0.50) in all the five studies were tested for association with CRC. To directly evaluate the imputation quality for the top four SNPs identified in our study, we genotyped them in approximately 2,500 samples included in Stage 1. The agreement of genotype calls derived from direct genotyping and imputation was very high, with a mean value of 98.05%, 95.61%, 99.84%, and 97.90% for rs647161, rs10774214, rs2423279, and rs1665650, respectively ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}).

Statistical analyses {#S10}
--------------------

Dosage data for genotyped and imputed SNPs for participants in each Stage 1 study were analyzed using the program mach2dat ^[@R18]^(see **URLs**). We coded 0, 1, or 2 copies of the effect allele as dosage for genotyped SNPs, and for imputed SNPs, we used the expected number of copies of the effect allele as dosage score. This approach has been shown to give unbiased estimates in meta-analyses ^[@R42]^. Associations between SNPs and CRC risk were assessed using odds ratios (ORs) and 95% confidence intervals (CIs) derived from logistic regression models. ORs were estimated based on the log-additive model and adjusted for age, sex, and the first ten principal components. PLINK version 1.07 (see **URLs**) also was used to analyze genotype data ^[@R43]^ and yielded results virtually identical to those derived from dosage data using mach2dat ^[@R18]^. Meta-analyses were performed using the inverse-variance method, assuming a fixed-effects model, and calculations were implemented in the METAL package ^[@R19]^ (see **URLs**).

Similar to Stage 1, we used logistic regression models to derive ORs and 95% CIs for the 64 selected SNPs in Stage 2, assuming a log-additive model with adjustment for age and sex. We performed joint analyses to generate summary results for combined samples from all studies with additional adjustment for study site. We also conducted stratification analysis for the top four SNPs by population ethnicity (Chinese, Korean, and Japanese) and by sex. We used Cochran's *Q* statistic to test for heterogeneity ^[@R44]^ and *I*^2^ statistic to quantify heterogeneity ^[@R45]^ across studies as described elsewhere in detail ^[@R46]^. Analyses for Stage 2, as well as combined Stages 1 and 2 data were conducted using SAS, version 9.2(see **URLs**), with the use of two-tailed tests. *P*-value 5×10^−8^ in the combined analysis was considered statistically significant.

We used Haploview version 4.2 ^[@R47]^(see **URLs**)to generate a genome-wide Manhattan plot for results from the Stage 1 meta-analysis. Forest plots and quantile-quantile (Q-Q) plots were drawn using R. We drew regional association plots using the website-based tool LocusZoom, version 1.1 ^[@R48]^ (see **URLs**). LD plots were generated using Haploview ^[@R47]^ and UCSC Genome Browser (see **URLs**).
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###### Regional plots of association results and recombination rates for the three SNPs showing evidence of an association with CRC risk

Genotyped and imputed data from GWAS samples are plotted based on their chromosomal position in NCBI Human Genome Build 36.3. For each region, the SNP selected for Stage 2 replication is denoted with a diamond, and *P*-value from the combined analysis of Stages 1 and 2 data is provided. Data are shown for (a) rs10774214, (b) rs647161, and (c) rs2423279.
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###### 

Association of colorectal cancer risk with the top four risk variants identified in East Asian samples

  SNP (alleles)[a](#TFN2){ref-type="table-fn"}   Chr. (gene)[b](#TFN3){ref-type="table-fn"}   Location (bp)[c](#TFN4){ref-type="table-fn"}   Stage    Cases   Controls            Per-allele association   Heterogeneity                                        
  ---------------------------------------------- -------------------------------------------- ---------------------------------------------- -------- ------- ------------------- ------------------------ --------------- ------------------- ------------- -- --
  rs10774214 (T/C)                               12p13.32 (*CCND2*)                           4,238,613                                      GWAS     2,098   0.373               5,749                    0.348           1.20 (1.09--1.32)   2.03×10^−4^      
  Replication                                    5,197                                        0.381                                          5,797    0.355   1.16 (1.09--1.23)   5.80×10^−7^                                                                   
  Overall                                        7,295                                        0.379                                          11,546   0.352   1.17 (1.11--1.23)   5.48×10^−10^             0.615           0%                                   
  rs647161 (A/C)                                 5q31.1 (*PITX1*)                             134,526,991                                    GWAS     2,098   0.353               5,749                    0.308           1.22 (1.12--1.33)   3.29×10^−6^      
  Replication                                    5,217                                        0.344                                          5,815    0.319   1.14 (1.07--1.21)   1.15×10^−5^                                                                   
  Overall                                        7,315                                        0.347                                          11,564   0.313   1.17 (1.11--1.22)   3.77×10^−10^             0.444           0%                                   
  rs2423279 (C/T)                                20p12.3 (*HAO1*)                             7,760,350                                      GWAS     2,098   0.339               5,749                    0.307           1.16 (1.07--1.26)   4.96×10^−4^      
  Replication                                    5,227                                        0.315                                          5,811    0.297   1.13 (1.06--1.19)   1.22×10^−4^                                                                   
  Overall                                        7,325                                        0.322                                          11,560   0.302   1.14 (1.08--1.19)   2.29×10^−7^              0.331           12%                                  
  rs1665650 (T/C)                                10q26.12 (*HSPA12A*)                         118,477,090                                    GWAS     2,098   0.346               5,749                    0.310           1.20 (1.10--1.31)   3.88×10^−5^      
  Replication                                    5,192                                        0.328                                          5,808    0.320   1.10 (1.04--1.17)   0.0018                                                                        
  Overall                                        7,290                                        0.333                                          11,557   0.315   1.13 (1.08--1.19)   8.58×10^−7^              0.404           4%                                   

Abbreviations: Chr., Chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.

Minor/major allele for East Asians, OR was estimated for the minor allele.

The closest gene.

Location based on NCBI Human Genome Build 36.3.

Adjusted for age, sex, the first ten principal components (Stage 1) and study site.

*P* for heterogeneity across studies in GWAS and Replication was calculated using a Cochran's *Q* test.

###### 

Association of colorectal cancer risk with the three newly-identified risk variants in European-ancestry populations and the meta-analyses of East Asians and Europeans

  SNP          Alleles[a](#TFN7){ref-type="table-fn"}   MAF[b](#TFN8){ref-type="table-fn"}   Europeans[c](#TFN9){ref-type="table-fn"}   East Asians and Europeans combined[c](#TFN9){ref-type="table-fn"}                                                                   
  ------------ ---------------------------------------- ------------------------------------ ------------------------------------------ ------------------------------------------------------------------- ------------------- ------- --------------- ------------------- --------------
  rs10774214   T/C                                      0.385                                0.379                                      11,870/14,190                                                       1.04 (1.00--1.09)   0.040   19,165/25,736   1.09 (1.06--1.13)   3.06×10^−8^
  rs647161     A/C                                      0.680                                0.667                                      11,870/14,190                                                       1.07 (1.02--1.11)   0.002   19,185/25,754   1.11 (1.08--1.15)   1.22×10^−10^
  rs2423279    C/T                                      0.263                                0.252                                      11,870/14,190                                                       1.07 (1.03--1.12)   0.001   19,195/25,750   1.10 (1.06--1.14)   6.64×10^−9^

Alelles (minor/major) as shown in [Table 2](#T2){ref-type="table"} for East Asians.

Minor allele frequency (MAF) in European-ancestry populations.

Summary statistics were generated using inverse-variance weighted, fixed-effects meta-analysis.
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